The challenge of sustainability in healthcare systems: cost of radiotherapy in the last month of life in an Italian cancer center.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
May 2021
Historique:
received: 24 03 2020
accepted: 26 08 2020
pubmed: 30 9 2020
medline: 20 4 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

Cost evaluation is becoming mandatory to support healthcare sustainability and optimize the decision-making process. This topic is a challenge, especially for complex and rapidly evolving treatment modalities such as radiotherapy (RT). The aim of the present study was to investigate the cost of RT in the last month of life of patients in an Italian cancer center. This was a retrospective study on a cancer population (N= 160) who underwent RT or only an RT planning simulation in an end of life (EOL) setting. The cost of RT procedures performed on patients was collected according to treatment status, care setting, and RT technique used. Costs were valued according to the sum of reimbursements relating to all procedures performed and assessed from the perspective of the National Health System. The total cost of RT in the last month of life was €244,774, with an average cost per patient of €1530. Around 7.7% and 30.3% of the total cost was associated with patients who never started RT or who discontinued RT, respectively, while the remaining 62.0% referred to patients who completed treatment. Costs associated with outpatient and inpatient settings represented 54.3% and 38.6% of the total cost, respectively. The higher average cost per patient for the never-started and discontinued groups was correlated with patients who had a poor ECOG Performance Status. Improved prognostic accuracy and a better integration between radiotherapy and palliative care units could be a key to a better use of resources and to a reduction in the cost of EOL RT.

Identifiants

pubmed: 32989523
doi: 10.1007/s00520-020-05718-0
pii: 10.1007/s00520-020-05718-0
pmc: PMC7981311
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2735-2742

Références

Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):895-906
pubmed: 8478242
Can Respir J. 2014 May-Jun;21(3):165-70
pubmed: 24367791
J Clin Oncol. 2003 Mar 15;21(6):1133-8
pubmed: 12637481
Radiother Oncol. 2017 Nov;125(2):186-192
pubmed: 28923574
Cancer. 2012 Sep 1;118(17):4339-45
pubmed: 22252390
Appl Health Econ Health Policy. 2014 Oct;12(5):497-510
pubmed: 25060829
Eur Urol. 2017 Nov;72(5):712-735
pubmed: 28366513
J Clin Oncol. 2011 Apr 20;29(12):1587-91
pubmed: 21402603
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
J Clin Oncol. 2004 Jan 15;22(2):315-21
pubmed: 14722041
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):654-62
pubmed: 27131080
Anticancer Res. 2014 Feb;34(2):877-85
pubmed: 24511026
Palliat Med. 2018 Sep;32(8):1389-1400
pubmed: 29793393
J Clin Oncol. 2008 Aug 10;26(23):3860-6
pubmed: 18688053
J Oncol Pract. 2014 Jul;10(4):e269-76
pubmed: 24756144
J Pain Symptom Manage. 2017 Jan;53(1):25-32
pubmed: 27720786
J Clin Oncol. 2013 Jan 1;31(1):80-7
pubmed: 23169520
CA Cancer J Clin. 2014 Sep-Oct;64(5):296-310
pubmed: 25043971
Clin Colorectal Cancer. 2017 Dec;16(4):386-396.e1
pubmed: 28619608
Radiother Oncol. 2019 Jul;136:154-160
pubmed: 31015119
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
Rev Assoc Med Bras (1992). 2018 Apr;64(4):318-323
pubmed: 30133610
Int J Qual Health Care. 2005 Dec;17(6):505-9
pubmed: 15985505
BMJ. 2003 Jul 26;327(7408):195-8
pubmed: 12881260
Eur J Cancer. 2016 Dec;69:110-118
pubmed: 27821313
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
JAMA. 1996 Jun 26;275(24):1907-14
pubmed: 8648872
Int J Qual Health Care. 2016 Sep;28(4):456-69
pubmed: 27353273
Health Technol Assess. 2010 Oct;14(47):1-108, iii-iv
pubmed: 21029717
Radiother Oncol. 2016 Dec;121(3):468-474
pubmed: 28007378
Radiother Oncol. 2008 Feb;86(2):217-23
pubmed: 18237802
J Clin Oncol. 2014 Sep 10;32(26):2913-9
pubmed: 25113773
Radiother Oncol. 2017 Nov;125(2):193-199
pubmed: 29050955
Lancet Oncol. 2006 Jul;7(7):584-95
pubmed: 16814210
Curr Oncol. 2016 Jun;23(3):e228-38
pubmed: 27330359
Value Health. 2008 Sep-Oct;11(5):791-9
pubmed: 18194407
BMC Palliat Care. 2018 Jun 19;17(1):86
pubmed: 29914452

Auteurs

Romina Rossi (R)

Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Valentina Danesi (V)

Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Ilaria Massa (I)

Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, Meldola, FC, 47014, Italy. ilaria.massa@irst.emr.it.

William Balzi (W)

Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Antonino Romeo (A)

Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Flavia Foca (F)

Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Oriana Nanni (O)

Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Marco Maltoni (M)

Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Mattia Altini (M)

Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, Meldola, FC, 47014, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH